Halozyme Therapeutics Inc. (HALO)
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HALO or FOLD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
HALO vs. FOLD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors?
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?
Here is how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance.
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
